See more : N.D. Rubber Public Company Limited (NDR.BK) Income Statement Analysis – Financial Results
Complete financial analysis of BioCardia, Inc. (BCDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioCardia, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Brompton Oil Split Corp. (OSP.TO) Income Statement Analysis – Financial Results
- Forum Engineering Inc. (7088.T) Income Statement Analysis – Financial Results
- American States Water Company (AWR) Income Statement Analysis – Financial Results
- KushCo Holdings, Inc. (KSHB) Income Statement Analysis – Financial Results
- Hamon & Cie (International) SA (HAMO.BR) Income Statement Analysis – Financial Results
BioCardia, Inc. (BCDA)
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 477.00K | 1.35M | 1.02M | 145.00K | 710.00K | 625.00K | 479.00K | 576.00K | 517.00K | 427.00K | 268.00K | 62.00K | 12.00K | 0.00 | 1.87M | 1.27M | 643.00K | 0.00 | 0.00 | 0.00 | 3.76M | 4.08M | 3.96M | 3.87M | 3.99M | 4.20M | 3.80M | 3.40M | 3.15M |
| Cost of Revenue | 7.73M | 11.90M | 640.00K | 4.00K | 358.00K | 517.00K | 690.00K | 746.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 380.00K | 197.00K | 130.00K | 0.00 | 0.00 | 0.00 | 860.33K | 1.01M | 971.26K | 952.26K | 898.17K | 1.00M | 900.00K | 800.00K | 727.61K |
| Gross Profit | -7.25M | -10.55M | 375.00K | 141.00K | 352.00K | 108.00K | -211.00K | -170.00K | 517.00K | 427.00K | 268.00K | 62.00K | 12.00K | 0.00 | 1.49M | 1.07M | 513.00K | 0.00 | 0.00 | 0.00 | 2.90M | 3.07M | 2.99M | 2.91M | 3.09M | 3.20M | 2.90M | 2.60M | 2.42M |
| Gross Profit Ratio | -1,519.71% | -780.25% | 36.95% | 97.24% | 49.58% | 17.28% | -44.05% | -29.51% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 79.67% | 84.46% | 79.78% | 0.00% | 0.00% | 0.00% | 77.12% | 75.32% | 75.46% | 75.37% | 77.48% | 76.19% | 76.32% | 76.47% | 76.89% |
| Research & Development | 7.73M | 8.83M | 8.56M | 9.81M | 8.56M | 8.45M | 5.80M | 3.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 1.33M | 215.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.73M | 0.00 | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.40M | 4.42M | 5.09M | 5.86M | 6.00M | 5.76M | 6.40M | 4.11M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 5.59M | 3.91M | 610.00K | 79.80K | 98.18K | 101.48K | 3.59M | 3.58M | 4.14M | 4.93M | 4.90M | 4.30M | 4.00M | 3.20M | 2.21M |
| Other Expenses | 0.00 | -6.00K | -2.00K | -2.00K | -2.00K | -3.00K | 2.00K | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.37K | 0.00 | 85.72K | 0.00 | 0.00 | 0.00 | 115.45K | 100.00K | 100.00K | 100.00K | 0.00 |
| Operating Expenses | 12.12M | 13.25M | 13.65M | 15.67M | 14.57M | 14.21M | 12.19M | 7.44M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 6.59M | 5.25M | 825.00K | 79.80K | 92.80K | 101.48K | 3.68M | 3.58M | 4.14M | 4.93M | 5.02M | 4.40M | 4.10M | 3.30M | 2.21M |
| Cost & Expenses | 12.12M | 13.25M | 13.65M | 15.67M | 14.92M | 14.73M | 12.88M | 8.18M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 6.97M | 5.44M | 955.00K | 79.80K | 92.80K | 101.48K | 4.54M | 4.58M | 5.11M | 5.88M | 5.91M | 5.40M | 5.00M | 4.10M | 2.94M |
| Interest Income | 0.00 | 0.00 | 9.00K | 21.00K | 87.00K | 118.00K | 95.00K | 0.00 | 3.00K | 3.00K | 10.00K | 8.00K | 11.00K | 0.00 | 0.00 | 0.00 | 33.00K | 4.36K | 5.37K | 1.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.00K | 0.00 | 3.00K | 112.00K | 0.00 | 95.00K | 1.74M | 3.00K | 3.00K | 10.00K | 8.00K | 25.00K | 27.00K | 24.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.00K |
| Depreciation & Amortization | 84.00K | 377.00K | 640.00K | 566.00K | 551.00K | 203.00K | 78.00K | 39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 11.00K | 967.00K | 1.21M | 561.00K | 61.00K | 0.00 | 0.00 | 0.00 | 71.08K | 84.93K | 101.83K | 107.91K | 115.45K | 100.00K | 100.00K | 100.00K | 49.74K |
| EBITDA | -11.56M | -11.82M | -12.57M | -14.44M | -14.05M | -13.90M | -12.23M | -8.54M | 319.00K | 231.00K | 9.00K | -339.00K | -618.00K | 384.00K | -3.90M | -3.61M | -218.00K | -79.80K | -92.80K | -101.48K | -99.79K | -443.03K | -418.80K | -1.05M | -1.91M | -1.81M | -1.10M | -1.00M | -600.00K |
| EBITDA Ratio | -2,423.48% | -880.25% | -1,237.73% | -10,649.66% | -1,974.23% | -2,223.84% | -2,573.49% | -1,146.70% | 61.70% | 54.10% | 3.36% | -546.77% | -5,058.33% | 0.00% | -208.40% | -170.11% | -33.90% | 0.00% | 0.00% | 0.00% | -18.08% | -10.86% | -24.66% | -50.88% | -54.95% | -23.81% | -42.11% | -17.65% | 9.25% |
| Operating Income | -11.64M | -11.90M | -12.63M | -15.53M | -14.21M | -14.10M | -12.41M | -7.61M | 319.00K | 231.00K | 9.00K | -339.00K | -618.00K | -583.00K | -5.10M | -5.63M | -312.00K | -79.80K | -92.80K | -101.48K | -779.68K | -503.74K | -1.15M | -2.02M | -1.93M | -1.20M | -1.20M | -700.00K | 206.23K |
| Operating Income Ratio | -2,441.09% | -880.25% | -1,244.33% | -10,709.66% | -2,001.83% | -2,256.32% | -2,589.77% | -1,320.83% | 61.70% | 54.10% | 3.36% | -546.77% | -5,150.00% | 0.00% | -272.98% | -444.16% | -48.52% | 0.00% | 0.00% | 0.00% | -20.74% | -12.35% | -29.13% | -52.20% | -48.28% | -28.57% | -31.58% | -20.59% | 6.55% |
| Total Other Income/Expenses | 73.00K | -6.00K | 7.00K | 525.00K | -496.00K | 115.00K | 97.00K | -2.70M | 3.00K | 3.00K | 10.00K | 8.00K | -14.00K | 27.00K | 24.00K | -20.00K | 33.00K | -199.20K | 0.00 | 0.00 | 679.90K | 24.23K | 24.23K | 56.84K | 56.84K | 625.51K | 500.00K | 0.00 | 839.12K |
| Income Before Tax | -11.57M | -11.91M | -12.62M | -15.00M | -14.71M | -13.99M | -12.31M | -10.31M | 322.00K | 234.00K | 19.00K | -331.00K | -632.00K | -556.00K | -5.08M | -5.80M | -279.00K | 0.00 | 0.00 | 0.00 | -722.70K | -479.51K | -1.23M | -1.96M | -1.54M | -1.30M | -700.00K | 0.00 | 139.12K |
| Income Before Tax Ratio | -2,425.79% | -880.70% | -1,243.65% | -10,347.59% | -2,071.69% | -2,237.92% | -2,569.52% | -1,789.93% | 62.28% | 54.80% | 7.09% | -533.87% | -5,266.67% | 0.00% | -271.70% | -457.41% | -43.39% | 0.00% | 0.00% | 0.00% | -19.22% | -11.76% | -31.02% | -50.73% | -38.72% | -30.95% | -18.42% | 0.00% | 4.42% |
| Income Tax Expense | 0.00 | 6.00K | -2.00K | 1.00K | 110.00K | -115.00K | -192.00K | 5.40M | -6.00K | -6.00K | -20.00K | -652.00K | -10.31M | 10.90M | -48.00K | 3.10M | 0.00 | -4.36K | 92.80K | 710.86K | -28.24K | -48.45K | 149.87K | 103.91K | -762.83K | 200.00K | -1.10M | -100.00K | 3.53K |
| Net Income | -11.57M | -11.91M | -12.62M | -15.01M | -14.82M | -13.87M | -12.31M | -10.31M | 322.00K | 234.00K | 19.00K | 305.00K | 9.66M | -11.51M | -5.08M | -5.80M | -287.00K | -75.44K | -92.80K | -812.34K | -722.70K | -479.51K | -1.23M | -2.18M | -1.54M | -1.30M | -600.00K | -600.00K | 135.60K |
| Net Income Ratio | -2,425.79% | -881.14% | -1,243.45% | -10,348.28% | -2,087.18% | -2,219.52% | -2,569.52% | -1,789.93% | 62.28% | 54.80% | 7.09% | 491.94% | 80,516.67% | 0.00% | -271.70% | -457.41% | -44.63% | 0.00% | 0.00% | 0.00% | -19.22% | -11.76% | -31.02% | -56.35% | -38.72% | -30.95% | -15.79% | -17.65% | 4.31% |
| EPS | -8.19 | -10.08 | -11.19 | -22.24 | -39.38 | -48.80 | -43.54 | -166.33 | 27.86 | 20.50 | 1.78 | 28.61 | 906.29 | -1.08K | -528.72 | -742.35 | -34.84 | -8.21 | -10.10 | -98.42 | -92.38 | -61.30 | -156.91 | -275.16 | -237.12 | -210.36 | -97.17 | -117.32 | 0.38 |
| EPS Diluted | -8.19 | -10.08 | -11.19 | -22.24 | -39.38 | -48.80 | -43.54 | -166.33 | 27.86 | 20.50 | 1.78 | 28.61 | 906.29 | -1.08K | -528.72 | -742.35 | -34.84 | -8.21 | -10.10 | -98.42 | -92.38 | -61.30 | -156.15 | -275.16 | -237.12 | -204.63 | -97.17 | -113.64 | 0.38 |
| Weighted Avg Shares Out | 1.41M | 1.18M | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 61.99K | 11.56K | 11.41K | 10.66K | 10.66K | 10.66K | 10.66K | 9.60K | 7.81K | 8.24K | 9.19K | 9.19K | 8.25K | 7.82K | 7.82K | 7.82K | 7.92K | 6.51K | 6.18K | 6.18K | 5.11K | 360.60K |
| Weighted Avg Shares Out (Dil) | 1.41M | 1.18M | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 61.99K | 11.56K | 11.41K | 10.66K | 10.66K | 10.66K | 10.66K | 9.60K | 7.81K | 8.24K | 9.19K | 9.19K | 8.25K | 7.82K | 7.82K | 7.86K | 7.92K | 6.51K | 6.35K | 6.18K | 5.28K | 360.60K |
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
BioCardia announces that the USPTO has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date.
BioCardia Announces Reverse Stock Split
SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that, following approval by the Company's stockholders and its Board of Directors,...
BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript
BioCardia, Inc. (NASDAQ:BCDA ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Miranda Peto - IR Peter Altman - President and CEO David McClung - CFO Conference Call Participants Lander Egaña-Gorroño - H.C. Wainwright Operator...
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2024 and filed its quarterly...
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the the three months ended...
BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the...
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial
BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript
BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2023 and filed its...
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2023...
Source: https://incomestatements.info
Category: Stock Reports